RETA
$93.02
Reata Pharma
$1.89
2.07%
RETA
Earnings Whisper ®
N/A
2nd Quarter June 2023
Consensus:  ($2.66)
Revenue:  $0.77 Mil
Wednesday
Aug 9
6:40 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RETA reports earnings?
Beat
Meet
Miss

Where is RETA's stock price going from here?
Up
Flat
Down
Stock chart of RETA
Analysts
Summary of analysts' recommendations for RETA
Score
Grade
Pivots
Resistance
$98.63
$96.15
$94.58

$92.10

Support
$90.53
$88.05
$86.48
Tweet
Growth
Description
Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates - bardoxolone methyl (bardoxolone) and omaveloxolone for rare forms of chronic kidney disease (CKD) and neurological diseases, respectively.